Eli Lilly's stock surged 4.5% to $1287.23 today, driven by continued investor enthusiasm following robust second-quarter earnings where revenue jumped 48%. - The company has also raised its 2026 revenue guidance to a midpoint of $86 billion. - Recent strategic initiatives, including a $370 million deal for ion channel collaboration and European approval for a weight-loss pill, are further boosting investor confidence.